Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)

Abstract Background The pro-inflammatory cytokines interleukin (IL)-4 and IL-13 and their cognate receptor IL-4 receptor-alpha are key targets for asthma therapy. Elarekibep is an inhaled Anticalin protein developed to inhibit IL-4 receptor-alpha signalling in patients with moderate-to-severe asthma...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Tania Hugo, Andrew R Harper, Jacob Leander, Philip Gardiner, Robert Palmér, Pål Lundin, David Bock, Xiao-Hong Zhou, Irina Bondarenko, Steve Burns, Erol Wiegert, Mary F Fitzgerald, David R Close, David J Keeling, Hitesh Pandya, Maria G Belvisi, Paul M O’Byrne
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2026-04-01
Цуврал:	Respiratory Research
Нөхцлүүд:	moderate-to-severe asthma inhaled biologics IL-4Rα
Онлайн хандалт:	https://doi.org/10.1186/s12931-026-03613-6
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!